Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198496 | 0.85 | TK1 (0.38) | ALDH1A1HSD17B10KDM4EHPGDADRA1A | |
| SCHEMBL7192987 | 0.76 | KDM4E (0.48) | ALDH1A1HSD17B10KDM4EHPGDADRA1A | |
| Acetic Acid SCHEMBL28553746 | 0.76 | CYP2C19 (0.48) | ALDH1A1HSD17B10KDM4EHPGDADRA1A | |
| SCHEMBL9566539 | 0.76 | PNP (0.60) | ALDH1A1HSD17B10TK1BLMMEN1 | |
| SCHEMBL12193833 | 0.76 | CCNE1 (0.48) | ALDH1A1HSD17B10KDM4EHPGDADRA1A | |
| Penciclovir SCHEMBL3495 | 0.75 | TK1 (0.70) | ALDH1A1HSD17B10TK1BLMMEN1 | |
| SCHEMBL8165314 | 0.75 | PNP (0.56) | ALDH1A1RXFP1CYP3A4SMN1; SMN2HIF1A | |
| Penciclovir SCHEMBL583037 | 0.74 | TK1 (0.69) | ALDH1A1HSD17B10TK1BLMMEN1 | |
| Penciclovir SCHEMBL10414021 | 0.74 | TK1 (0.69) | ALDH1A1HSD17B10TK1BLMMEN1 | |
| Penciclovir SCHEMBL7192792 | 0.74 | TK1 (0.69) | ALDH1A1HSD17B10TK1BLMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | disclosed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | QUADEX PHARMACEUTICALS, LLC | 2015-12-31 | — | — | US | disclosed |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC | 2015-12-03 | — | — | US | disclosed |
| US-9125911-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2014160369-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-6579981-B1 | Treating herpes virus | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-06-17 | — | — | US | disclosed |
| US-6573378-B1 | 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine having a purity of greater than 95% by weight or it's sodium salt | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2003-06-03 | — | — | US | disclosed |
| EP-0141927-B1 | ANTIVIRAL GUANINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1991-10-30 | — | — | EP | disclosed |
| EP-0141927-A2 | Antiviral guanine derivatives | BEECHAM GROUP PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274939-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | SAMHD1, DCTD, NT5E | ALDH1A1 3928/4885HSD17B10 3681/4885KDM4E 3252/4885 |
| US-20150342955-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | NT5E, SAMHD1, DCTD | ALDH1A1 3897/4885HSD17B10 3879/4885KDM4E 2688/4885 |
| US-20150374704-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED AND/OR PRODROMAL STAGE TISSUE | SAMHD1, CUTA, TK1 | ALDH1A1 4317/4885HSD17B10 4458/4885KDM4E 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.